Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.

ABSTRACT:

Background

ChAdOx1-vectored vaccine candidates against several pathogens have been developed and tested in clinical trials and ChAdOx1 nCoV-19 has now been licensed for emergency use for COVID-19. We assessed the safety and immunogenicity of the ChAdOx1 MERS vaccine in a phase 1b trial in healthy Middle Eastern adults.

Method

MERS002 is an open-label, non-randomised, dose-escalation, phase 1b trial. Healthy Middle Eastern adults aged 18-50 years were included in the study. ChAdOx1 MERS was administered as a single intramuscular injection into the deltoid muscle of the non-dominant arm at three different dose groups: 5·0 × 10⁹ viral particles in a low-dose group, 2·5 × 10¹⁰ viral particles in an intermediate-dose group, and 5·0 × 10¹⁰ viral pa

SUBMITTER: Bosaeed M 

PROVIDER: S-EPMC8565931 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature